UPMC

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Retrieved on: 
Tuesday, April 2, 2024
Q&A, Primary sclerosing cholangitis, Liver disease, UC, UPMC, KOL, PSC, Doctor of Philosophy, Digestate, CCL24, Clinical trial, Therapy, CMMB, Liver, University of California, Davis, FDA, TEL, Pharmaceutical industry

TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET. To register, click here.

Key Points: 
  • —“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
    TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET.
  • They will discuss the urgent need for new PSC treatments and emerging developments that could facilitate new drug approvals.
  • Chemomab’s co-founder, CEO & CSO Adi Mor, PhD and CMO Matt Frankel, MD, will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024.
  • CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that is a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases.

Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Consultant, CRH, Ovarian cancer, Conference call, Conference, Survival, Science, Intelligence, Drug discovery, Webcast, BIO, Research, Holocene, UPMC, KOL, G&A, Call, GMP, UPMC Magee-Womens Hospital, Cloud computing, CLIA, Drug development, Machine learning, Marketing, Artificial intelligence, Cryptocurrency

The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.

Key Points: 
  • The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.
  • “Perhaps most notably, we announced last quarter that we successfully delivered the results of our first campaign with Cancer Research Horizons.
  • Revenues for the years ended December 31, 2023, and December 31, 2022, were primarily derived from its Eagan operating segment.
  • Conference call and webcast details:
    Predictive Oncology management will host an investor conference call and webcast on Monday, April 1st, at 8:30am EDT.

Synchron Launches Patient Registry for Stentrode Brain Computer Interface

Retrieved on: 
Monday, April 8, 2024
Medical Devices, Health, Neurology, Health Technology, Other Health, Biotechnology, Brain, BCI, Motor cortex, Communication, Patient, UPMC, University, Disability studies, Movement, Physician, Pathology, Medical device

The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility.

Key Points: 
  • The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility.
  • By leveraging the natural highways of the brain, an individual’s blood vessels, the device is implanted in the brain without the need for invasive brain surgery.
  • “We are thrilled to launch our community-centered BCI registry,” said Tom Oxley, CEO & Founder, Synchron.
  • For more information about the Synchron BCI and our registry, visit https://synchronbci.com .

Sutter Health Partners with Abridge on Generative AI Solution to Improve Patient, Physician Experience

Retrieved on: 
Wednesday, March 27, 2024
Health, Technology, Telemedicine, Virtual Medicine, Health Technology, Health Insurance, Artificial Intelligence, Emory Healthcare, Patient, Research, UPMC, News, Sutter Health, AI, University, Abridge, Multimedia, Physician, Pharmaceutical industry

Today, Abridge and Sutter Health announced they will make Abridge’s generative AI platform for clinical documentation available to groups of its physicians across California.

Key Points: 
  • Today, Abridge and Sutter Health announced they will make Abridge’s generative AI platform for clinical documentation available to groups of its physicians across California.
  • Sutter Health expects the broad deployment to improve patients’ experiences by helping support more focused face-time with clinicians.
  • “There is tremendous momentum behind our collective efforts, and it has the ability to change lives for the better,” said Warner Thomas, president and CEO, Sutter Health.
  • “We want to support our clinicians so they can sustainably serve our patients,” said Dr. Albert Chan, chief health information officer, Sutter Health.

Insights on Leading Employers in Top Business Sectors and Insurers that Serve Them by Mark Farrah Associates

Retrieved on: 
Monday, March 25, 2024
Public Policy, Government, Insurance, Finance, General Health, Health, Healthcare Reform, Banking, Professional Services, Blue Shield, Fashion merchandising, Welfare, Retail, Walmart, MFA, Internal Revenue Service, UPMC, Mass General Brigham, ERISA, Average revenue per user, Health care, Mass, Health insurance

Mark Farrah Associates (MFA), www.markfarrah.com , presents a high-level analysis of the leading employers in top business sectors, as well as the key health benefit insurers that serve them, utilizing information from MFA’s 5500 Employer Health Plus product.

Key Points: 
  • Mark Farrah Associates (MFA), www.markfarrah.com , presents a high-level analysis of the leading employers in top business sectors, as well as the key health benefit insurers that serve them, utilizing information from MFA’s 5500 Employer Health Plus product.
  • Large private-sector employers providing health and welfare benefit plans subject to ERISA are required to file the annual Form 5500 with the Internal Revenue Service.
  • Observations obtained from 5500 Employer Health Plus are based on 86,200 employers that indicated they had active health benefit contracts as of their most recent filings.
  • Private-sector employers reported 89.7 million potential plan participants across the spectrum of all health benefit contracts.

Abridge and UCI Health Bring Trusted AI-Powered Clinical Notes System-Wide

Retrieved on: 
Wednesday, March 13, 2024
Technology, Hospitals, Health Technology, Software, Practice Management, Health, General Health, Data Management, Artificial Intelligence, Emory Healthcare, Trust, Patient, Interface (computing), Research, UPMC, News, University, Medicine, Multimedia, Medical device

Abridge has announced that UCI Health, the health system of the University of California, Irvine, has adopted its leading generative AI solution for clinical documentation.

Key Points: 
  • Abridge has announced that UCI Health, the health system of the University of California, Irvine, has adopted its leading generative AI solution for clinical documentation.
  • The deployment will be focused on reducing the burden of clinical documentation and improving operational efficiency for clinicians across the system.
  • “Our deployment at UCI Health helps demonstrate the value of Abridge across a wide range of specialties, care settings, and languages.
  • ”Abridge is already reducing the ‘pajama time’ that is endemic to clinicians today,” said Scott Joslyn, Chief Innovation Officer, UCI Health.

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis

Retrieved on: 
Thursday, March 21, 2024
Diagnosis, Champalimaud Foundation, Cone Health Women's Hospital, PPV, Glomus tumor, Adenoma, Overdiagnosis, Incidence, Research, Cancer, Hospital, UPMC, Breast, Marie Cassidy, AI, University, Laboratory, MD, Oncology, Medicine, USCAP, OSU, Dysplasia, Brigham and Women's Hospital, Breast cancer, Ohio State University, Pathology, Champalimaud, Stomach, Artificial intelligence, Annual general meeting, NPV, Medical imaging

BOSTON, March 21, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women's Hospital, Champalimaud Foundation and Ohio State University (OSU). These studies, highlighting the value of Ibex's AI-powered cancer diagnostics solutions in both diagnostic quality and efficiency, will be presented next week at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting.

Key Points: 
  • Brigham and Women's Hospital and Champalimaud Foundation research shows high accuracy levels of Galen Breast in identifying microinvasive carcinoma of the breast.
  • Ohio State University Wexner Medical Center studies show high accuracy for Galen Breast and Galen Gastric in detecting and distinguishing between different types of cancer and in identifying multiple important pathologies.
  • In addition, researchers from OSU Wexner Medical Center will present studies validating Galen Breast's performance in detecting different types of breast cancer.
  • Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755.

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

Retrieved on: 
Monday, February 26, 2024
Science, Neurology, Biometrics, Biotechnology, Research, General Health, Health, Health Technology, Mass, Mass General Brigham, Hospital, AdventHealth, Alzheimer's disease, Doctor of Philosophy, Medical school, MD, Physician, Quality of life, UPMC, Biomarker, Mayo Clinic, Patient, CSF, Disease, Diagnosis, Plasma, Harvard Medical School, Corporation, Workflow, Medical imaging

These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.

Key Points: 
  • These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.
  • This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.
  • Traditional AD diagnosis has relied on combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD.
  • “In our pursuit to build the global testing infrastructure for Alzheimer’s disease, Quanterix is pleased to work with several health systems whose combined networks treat millions of patients,” said Masoud Toloue, CEO of Quanterix.

BrainCheck Secures $15 Million to Fuel Expansion and Adoption of its Next Generation Digital Cognitive Assessment and Care Planning Platform

Retrieved on: 
Wednesday, March 6, 2024
Caregiver, Dementia, New Board, Growth, UPMC, Entrepreneurship, Risk, Deficit spending, Patient, Management

AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- BrainCheck, Inc., a digital health innovator delivering first-of-its-kind technology into the growing digital cognitive assessment market, today announced a $15 million new financing round, led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC. The Company also expanded its Board of Directors with the appointment of Nicholas Shapiro, Vice President, UPMC Enterprises, as a new board member, further strengthening the Company's strategic leadership.

Key Points: 
  • This announcement follows the recent launch of BrainCheck's next generation platform and 3-minute screening solution, which empowers clinicians to screen and monitor patients' cognitive function anytime, anywhere.
  • "We thank our current and new investors for their continued support and look forward to deploying this capital to play an important role in revolutionizing cognitive care."
  • "We believe in BrainCheck's vision to pioneer a fundamental shift in how cognitive care is delivered," said Michael Smerklo, Co-Founder and Managing Partner of Next Coast Ventures.
  • For more information about BrainCheck and its innovative cognitive assessment solutions, please visit www.braincheck.com .

Attorney Sandra Neuman, of Sandra Neuman Law, secured a $1.4 million verdict against UPMC Passavant

Retrieved on: 
Saturday, March 2, 2024
Legal advice, Passavant, Safety, Fracture, Injury, Counsel, Multimedia, UPMC, Risk

PITTSBURGH, March 1, 2024 /PRNewswire-PRWeb/ -- On Thursday, February 29, an Allegheny County jury awarded a 62-year-old man from Mars, PA, $1.4 million in damages for negligence resulting from a fall that caused permanent injury to his dominant arm. The incident occurred when the man was admitted to UPMC Passavant for a scheduled hip surgery. His surgery had to be postponed due to low sodium levels. During this time, he was identified as a level 2 fall risk requiring bathroom supervision. He was escorted to the bathroom by two UPMC employees but then left alone. The fall caused a severe fracture to his dominant arm requiring extensive medical interventions, including three surgeries thus far with a looming fourth surgery, a fusion.

Key Points: 
  • Sandra Neuman Law secured a $1.4 million medical malpractice verdict against UPMC Passavant for negligence resulting from a fall that caused permanent injury to his dominant arm.
  • The incident occurred when the man was admitted to UPMC Passavant for a scheduled hip surgery.
  • Defense Counsel Fredrick Bode and Alyssa Dedola from Dickie McCamey & Chilcote represented UPMC Passavant.
  • Attorney Sandra Neuman , representing the plaintiff, uncovered internal UPMC documents highlighting critical lapses in care.